We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+18.77%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$5.81B
AUM Growth
+$81.2M
Cap. Flow
-$98.4M
Cap. Flow %
-1.69%
Top 10 Hldgs %
85.45%
Holding
128
New
20
Increased
23
Reduced
35
Closed
17
Avg Time Held Equity + Options
4.5 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.4 quarters
Avg Time Held Equity only
5.5 quarters
Top 10 Avg Time Held Equity only
6.1 quarters
Top 20 Avg Time Held Equity only
7.1 quarters

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.13M
2
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$6.85M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.62M
4
PRQR icon
ProQR Therapeutics
PRQR
+$5.19M
5
ARRY icon
Array Biopharma Inc
ARRY
+$5.11M

Top Sells

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$22.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$15M
3
ONC icon
BeOne Medicines Ltd
ONC
+$13M
4
BLUE icon
bluebird bio
BLUE
+$12.4M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$12.2M

Sector Composition

Rank Sector Weight
1 Consumer Staples 42.79%
2 Consumer Discretionary 22.09%
3 Healthcare 21.97%
4 Miscellaneous 13.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GBT
51
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.76M 0.13%
250,000
– –
2017 Q2
1 quarter
MDCO
52
CALL
DELISTED
Medicines Co
MDCO
$7.41M 0.13%
200,000
– –
2017 Q2
1 quarter
PRQR icon
53
ProQR Therapeutics
PRQR
$230M
$7.28M 0.13%
1,500,000
+1,000,000
+200% +$5.19M
2017 Q1
2 quarters
BLUE icon
54
CALL
DELISTED
bluebird bio
BLUE
$6.87M 0.12%
3,860
– –
2017 Q2
1 quarter
JUNO
55
DELISTED
Juno Therapeutics, Inc.
JUNO
$6.73M 0.12%
150,000
-50,000
-25% -$1.7M
2014 Q4
11 quarters
HZNP
56
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.34M 0.11%
500,000
– –
2017 Q2
1 quarter
HZNP
57
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.34M 0.11%
500,000
-260,000
-34% -$3.31M
2016 Q2
5 quarters
ALDR
58
DELISTED
Alder Biopharmaceuticals
ALDR
$6.13M 0.11%
500,000
+200,000
+67% +$2.09M
2017 Q1
2 quarters
BOLD icon
59
DELISTED
Audentes Therapeutics, Inc
BOLD
$5.6M 0.1%
+200,000
New +$4.34M
2017 Q3
0 quarters
ACIU icon
60
AC Immune
ACIU
$249M
$5.58M 0.1%
500,000
– –
2016 Q3
4 quarters
SGEN
61
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$5.44M 0.09%
100,000
– –
2017 Q2
1 quarter
RGNX icon
62
Regenxbio
RGNX
$533M
$5.27M 0.09%
160,000
– –
2015 Q3
8 quarters
ANAB icon
63
AnaptysBio
ANAB
$1.37B
$5.24M 0.09%
150,000
-100,000
-40% -$2.7M
2017 Q1
2 quarters
TGTX icon
64
TG Therapeutics
TGTX
$8.48B
$4.74M 0.08%
400,000
-100,000
-20% -$1.14M
2017 Q2
1 quarter
ELF icon
65
e.l.f. Beauty
ELF
$6.45B
$4.51M 0.08%
200,000
-50,000
-20% -$1.15M
2016 Q3
4 quarters
AXDX icon
66
DELISTED
Accelerate Diagnostics
AXDX
$4.49M 0.08%
20,000
– –
2017 Q2
1 quarter
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$4.49M 0.08%
+1,000,000
New +$4.44M
2017 Q3
0 quarters
IMUX icon
68
Immunic
IMUX
$112M
$4.42M 0.08%
2,188
– –
2017 Q1
2 quarters
NTLA icon
69
Intellia Therapeutics
NTLA
$1.83B
$4.35M 0.07%
175,000
-75,000
-30% -$1.41M
2016 Q2
5 quarters
ADAP
70
DELISTED
Adaptimmune Therapeutics
ADAP
$4.09M 0.07%
500,000
+200,000
+67% +$1.25M
2016 Q3
4 quarters
AKAO
71
DELISTED
Achaogen Inc
AKAO
$3.99M 0.07%
250,000
+50,000
+25% +$951K
2016 Q4
3 quarters
CCXI icon
72
DELISTED
ChemoCentryx, Inc.
CCXI
$3.71M 0.06%
500,000
– –
2013 Q2
17 quarters
MGNX icon
73
MacroGenics
MGNX
$238M
$3.7M 0.06%
200,000
-100,000
-33% -$1.73M
2016 Q3
4 quarters
LCTX icon
74
Lineage Cell Therapeutics
LCTX
$251M
$3.64M 0.06%
1,465,383
– –
2014 Q4
11 quarters
VSTM icon
75
Verastem
VSTM
$759M
$3.52M 0.06%
62,500
+20,833
+50% +$983K
2017 Q2
1 quarter
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2017 Portfolio in Review

As of Q3 2017, Artal Group held 128 positions worth $5.81B, up 1.4% from $5.72B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Artal Group's Q3 2017 filing shows 20 new, 23 increased, 35 reduced and 17 closed positions. Its largest new stake was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M. The largest sale was Goldman Sachs, an estimated $22.6M.

By sector, the portfolio is most concentrated in Consumer Staples at 43% of assets, up from 35% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q3 2017 buy was Achillion Pharmaceuticals: 1,000,000 shares worth $4.49M.
  • Artal Group added most to Clovis Oncology, Inc. in Q3 2017, an estimated $7.13M increase.
  • Artal Group's biggest Q3 2017 reduction was Agios Pharmaceuticals, cutting an estimated $15M.
  • Artal Group fully exited Goldman Sachs in Q3 2017, selling an estimated $22.6M.
  • Artal Group's ten largest holdings make up 85% of its $5.81B portfolio in Q3 2017.
  • Artal Group opened 20 new positions and closed 17 in Q3 2017.
  • Artal Group's portfolio value rose 1.4% quarter-over-quarter to $5.81B.

Based on Artal Group's 13F filing for Q3 2017, filed 8 Nov 2017.